The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study.
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; CPPC; Hengrui Pharm; Hutchison MediPharma; Innovent Biologics; Junshi Pharmaceuticals; Keymed Biosience; Merck Serono; MSD; QiLu Pharmaceutical; Roche
 
Feng Wang
No Relationships to Disclose
 
Gong Chen
No Relationships to Disclose
 
Meng Qiu
No Relationships to Disclose
 
Jinfeng Ma
No Relationships to Disclose
 
Haiyi Liu
No Relationships to Disclose
 
Xianwei Mo
No Relationships to Disclose
 
Yongqiang Li
No Relationships to Disclose
 
Xiangbin Wan
No Relationships to Disclose
 
Jia Luo
No Relationships to Disclose
 
Yingbin Hu
No Relationships to Disclose
 
Xiwen Huang
No Relationships to Disclose
 
Weiqin Jiang
No Relationships to Disclose
 
Leping Li
No Relationships to Disclose
 
Yanbing Zhou
No Relationships to Disclose
 
Xiaoxiao Lu
Employment - Innovent Biologics
 
Yuling Chen
Employment - Innovent Biologics
 
Qun Guo
Employment - Innovent Biologics
 
Li Li
No Relationships to Disclose
 
Hui Zhou
Employment - Innovent Biologics